TIDMOXB

RNS Number : 2639K

Oxford Biomedica PLC

09 April 2018

Director Dealings / Market Share Purchase

Oxford, UK - 09 April 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Stuart Paynter, Chief Financial Officer has purchased 87,626 ordinary shares of 1p each ("Ordinary Shares") in the Company on 09 April 2018 on the London Stock Exchange at a price of 11.2p per share. Following this purchase Stuart Paynter holds 87,626 ordinary shares representing 0.003% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

 
 1.   Details of the person discharging material 
       responsibilities/person closely associated 
----  ------------------------------------------------------------------ 
 a.   Name                              Stuart Paynter 
----  -------------------------------  --------------------------------- 
 2.   Reason for the notification 
----  ------------------------------------------------------------------ 
 a.   Position/status                   Chief Financial Officer 
----  -------------------------------  --------------------------------- 
 b.   Initial notification              Initial notification 
       /amendment 
----  -------------------------------  --------------------------------- 
3.    Details of the issuer, emission allowance, 
       market participant, auction platform, 
       auctioneer or auction monitor 
----  ------------------------------------------------------------------ 
 a.   Name                              Oxford BioMedica plc 
----  -------------------------------  --------------------------------- 
 b.   Legal Entity                      213800S1GVQNXQ15K851 
       Identifier 
----  -------------------------------  --------------------------------- 
4.    Details of the transaction(s); section 
       to be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) 
       each date; and (iv) each place where 
       transactions have been conducted 
----  ------------------------------------------------------------------ 
 a.   Description                       Oxford BioMedica plc Ordinary 
       of the financial                  Shares of 1p each 
       instrument,                       GB0006648157 
       type of instrument 
       identification 
       code 
----  -------------------------------  --------------------------------- 
b.    Nature of                         Purchase of ordinary shares 
       the transaction 
----  -------------------------------  --------------------------------- 
c.    Currency                          GBP - British Pound 
----  -------------------------------  --------------------------------- 
d.    Price(s) and                         Price(s)         Volume(s) 
       volume(s) 
----  -------------------------------  ----------------  --------------- 
                        GBP0.112                             87,626 
  -----------------------------------------------------  --------------- 
 
e.          Aggregated                  87,626 
             information                 GBP0.112 
              *    Aggregated volume     GBP9,814.11 
 
 
              *    Price 
 
 
              *    Aggregated total 
----  -------------------------------  --------------------------------- 
f.    Date of the                       2018-04-09 
       transaction 
----  -------------------------------  --------------------------------- 
g.    Place of the                      London Stock Exchange, Main 
       transaction                       Market (XLON) 
----  -------------------------------  ---------------------------------

The issued share capital of the Group is 3,283,790,680 ordinary 1p shares.

-Ends-

 
 For further information, 
  please contact: 
  Oxford BioMedica plc:                     Tel: +44 (0)1865 
   John Dawson, Chief Executive              783 000 
   Officer 
   Stuart Paynter, Chief Financial 
   Officer 
  Financial and corporate communications    Tel: +44 (0)20 3709 
   enquiries:                                5700 
   Consilium Strategic Communications 
   Mary-Jane Elliott/Matthew 
   Neal/Philippa Gardner/Laura 
   Thornton

Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHGCGDSUSGBGIC

(END) Dow Jones Newswires

April 09, 2018 05:47 ET (09:47 GMT)

Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Oxford Biomedica Charts.
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Oxford Biomedica Charts.